137 POSTER Characterization of GSK1120212 a novel allosteric inhibitor of MEK1/2
Symon G. Erskine, Zengguang Lai, Cynthia M. Rominger(GlaxoSmithKline (United Kingdom)), Sylvie Laquerre(Johnson & Johnson (United States)), Francesca Zappacosta(South College), Peter J. Tummino(Intarcia Therapeutics (United States)), Jr J Adams
Cited by 0
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition
|Clinical Cancer Research|2011|600
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550